The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
Nilsson L., Edén P., Olsson E., Månsson R., Astrand-Grundström I., Strömbeck B., Theilgaard-Mönch K., Anderson K., Hast R., Hellström-Lindberg E., Samuelsson J., Bergh G., Nerlov C., Johansson B., Sigvardsson M., Borg A., Jacobsen SE.
Global gene expression profiling of highly purified 5q-deleted CD34+CD38(-)Thy1+ cells in 5q- myelodysplastic syndromes (MDSs) supported that they might originate from and outcompete normal CD34+CD38(-)Thy1+ hematopoietic stem cells. Few but distinct differences in gene expression distinguished MDS and normal stem cells. Expression of BMI1, encoding a critical regulator of self-renewal, was up-regulated in 5q- stem cells. Whereas multiple previous MDS genetic screens failed to identify altered expression of the gene encoding the myeloid transcription factor CEBPA, stage-specific and extensive down-regulation of CEBPA was specifically observed in MDS progenitors. These studies establish the importance of molecular characterization of distinct stages of cancer stem and progenitor cells to enhance the resolution of stage-specific dysregulated gene expression.